Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 17, 2020

Primary Completion Date

September 30, 2020

Study Completion Date

October 30, 2020

Conditions
COVID-19
Interventions
DRUG

Favipiravir

Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets

OTHER

Standard of Care

Standard of Care for individual study site as determined by each hospital's protocol

Trial Locations (8)

33136

University of Miami Miller School of Medicine, Miami

77030

Houston Methodist Hospital, Houston

85258

HonorHealth, Scottsdale

02118

Boston Medical Center, Boston

02215

Brigham and Women's Hospital, Boston

Massachusetts General Hospital, Boston

01605

UMass Memorial Health Care, Worcester

07960

Atlantic Health System / Morristown Medical Center, Morristown

All Listed Sponsors
lead

Fujifilm Pharmaceuticals U.S.A., Inc.

INDUSTRY